Microgreen Consumption for Healthy Aging

What this trial studies

Microgreens are an emerging horticultural food crop with potential to improve human health. Previous research suggests they have broad consumer acceptance and that the micronutrient and bioactive compound levels are higher than that of their mature counterparts. To date, no studies have explored the feasibility of microgreen consumption, gastrointestinal tolerance of microgreen consumption, or their potential health impacts in humans. Therefore, the overall goal of this study is to explore the feasibility and acceptability of daily microgreen consumption, gastrointestinal tolerability, and potential health impacts of red cabbage and red beet microgreens in healthy middle-aged/older men and postmenopausal women - a population inherently at risk for chronic disease, e.g.

Conditions in scope

• Aging
• Menopause
• Healthy

Interventions

• Red cabbage microgreens (Other) — 2 cups per day
• Red beet microgreens (Other) — 2 cups per day

Who can join

All sexes · Ages 45 Years to 70 Years · Accepts healthy volunteers.

Inclusion criteria

• Male or postmenopausal
• Aged 45-70

Exclusion criteria

• Cardiovascular disease, hypertension, diabetes, neuropathy, thrombosis, cancer, gastrointestinal, kidney, liver, lung, or pancreatic disease
• Taking medication for high cholesterol, triglycerides, or blood sugar, or are taking testosterone medications
• Blood pressure ≥ 130/80 mm Hg, triglyceride levels \> 200 mg/dL, low-density lipoprotein cholesterol levels ≥ 160 mg/dL, total cholesterol levels ≥ 240 mg/dL, and/or hemoglobin A1c ≥ 6.5%
• Weight change ≥ 3 kg (6.6 lb.) in the past 3 months prior to starting the study, are actively trying to lose weight, or are unwilling to remain weight stable throughout the study
• Have a BMI less than 18.5 or greater than 30 kg/m2
• Are not willing to maintain normal eating/drinking and exercise habits over the duration of the study
• Currently smoke cigarettes or have a history of smoking cigarettes in the past 12 months
• Taking antibiotics or have taken them within one month of starting the study

Eligibility wording paraphrased from the public record. View the full criteria on ClinicalTrials.gov before contacting a site.

Where it’s happening

Status & timeline

• Overall status: Completed
• Study type: Interventional
• Phase: N/A
• Start date: 2019-07-16
• Primary completion: 2019-11-22
• Last update posted: 2024-09-19
• First posted: 2020-01-27

Sponsor & contact

Lead sponsor: Colorado State University (Other)

For trial site contact information, use the official record at ClinicalTrials.gov. Contact details change frequently and the public record is the source of truth.

Outcome measures

Primary outcomes

• Number of participants retained (Baseline to 6 weeks)
  The number of participants retained versus lost to follow-up throughout the entire study
• Adherence to the intervention (Baseline to 2 weeks)
  Adherence will be determined for each 2-week microgreen intervention through a daily microgreen consumption log

Related ClearedRx care

If you’re reading this trial because you have menopause symptoms now, you don’t have to wait for a trial to access evidence-based care. ClearedRx prescribes the same FDA-approved and compounded HRT products that have been studied in trials like this one for decades.